 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...30313233343536373839404142 |
- anastrozole / Generic mfg.
New P2 trial: Anastrozole in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 4, 2012
P2, N=18, Recruiting, Sponsor: University of Pennsylvania
- | anastrozole / Generic mfg.
Enrollment change: IBIS II: Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer (clinicaltrials.gov) - Feb 28, 2012
P3, N=3864, Active, not recruiting, Sponsor: Jill Knox
N=6000 --> 3864
- | anastrozole / Generic mfg., tamoxifen / Generic mfg.
Enrollment change: IBIS-II DCIS: Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ (clinicaltrials.gov) - Feb 28, 2012
P3, N=2980, Active, not recruiting, Sponsor: Jill Knox
N=6000 --> 3864 N=4000 --> 2980
- | anastrozole / Generic mfg.
Enrollment closed: IBIS II: Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer (clinicaltrials.gov) - Feb 28, 2012
P3, N=3864, Active, not recruiting, Sponsor: Jill Knox
N=4000 --> 2980 Recruiting --> Active, not recruiting
- | anastrozole / Generic mfg., tamoxifen / Generic mfg.
Enrollment closed: IBIS-II DCIS: Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ (clinicaltrials.gov) - Feb 28, 2012
P3, N=2980, Active, not recruiting, Sponsor: Jill Knox
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- anastrozole / Generic mfg.
Enrollment change: Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure (clinicaltrials.gov) - Jan 26, 2012
P2, N=150, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting N=50 --> 150
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Enrollment change: Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer (clinicaltrials.gov) - Jan 25, 2012
P2, N=51, Completed, Sponsor: University of Maryland
N=50 --> 150 N=100 --> 51
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion: Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer (clinicaltrials.gov) - Jan 25, 2012
P2, N=51, Completed, Sponsor: University of Maryland
N=100 --> 51 Recruiting --> Completed
- ||| anastrozole / Generic mfg.
Trial completion, Compliance: Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT) (clinicaltrials.gov) - Jan 9, 2012
P=N/A, N=2313, Completed, Sponsor: AstraZeneca
Recruiting --> Completed Active, not recruiting --> Completed
- |||| anastrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion: HEART: Liver Safety Under Upfront Arimidex vs Tamoxifen (clinicaltrials.gov) - Jan 2, 2012
P4, N=384, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Enrollment closed, Surgery: Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Dec 22, 2011
P3, N=610, Active, not recruiting, Sponsor: American College of Surgeons
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- letrozole / Generic mfg., anastrozole / Generic mfg.
Trial completion: Anastrozole and Letrozole (clinicaltrials.gov) - Dec 13, 2011
P=N/A, N=25, Completed, Sponsor: University of Connecticut Health Center
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- letrozole / Generic mfg., anastrozole / Generic mfg.
Enrollment change: Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy (clinicaltrials.gov) - Nov 30, 2011
P=N/A, N=72, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=50 --> 72
- | dovitinib (TKI258) / Novartis, Oncoheroes
New P1/2 trial, Combination therapy, Metastases: Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer (clinicaltrials.gov) - Nov 30, 2011
P1/2, N=36, Recruiting, Sponsor: Georgetown University
- letrozole / Generic mfg., anastrozole / Generic mfg.
Trial completion: Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy (clinicaltrials.gov) - Nov 30, 2011
P=N/A, N=72, Completed, Sponsor: City of Hope Medical Center
N=50 --> 72 Active, not recruiting --> Completed
- || anastrozole / Generic mfg.
Enrollment change, Adherence: ARIADNE: Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence (clinicaltrials.gov) - Nov 14, 2011
P=N/A, N=1077, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed N=1500 --> 1077
- ||| anastrozole / Generic mfg.
Trial completion, Adherence: ARIADNE: Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence (clinicaltrials.gov) - Nov 14, 2011
P=N/A, N=1077, Completed, Sponsor: AstraZeneca
N=1500 --> 1077 Active, not recruiting --> Completed
- | anastrozole / Generic mfg., fulvestrant / Generic mfg.
Trial termination, Combination therapy, Monotherapy: Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole (clinicaltrials.gov) - Oct 24, 2011
P3, N=872, Terminated, Sponsor: Spanish Breast Cancer Research Group
Active, not recruiting --> Completed Suspended --> Terminated; Unjustified decision of company that funded the trial.
- | anastrozole / Generic mfg., fulvestrant / Generic mfg.
Enrollment change, Combination therapy, Monotherapy: Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole (clinicaltrials.gov) - Oct 24, 2011
P3, N=872, Terminated, Sponsor: Spanish Breast Cancer Research Group
Suspended --> Terminated; Unjustified decision of company that funded the trial. N=3180 --> 872
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca. (clinicaltrials.gov) - Sep 25, 2011
P2, N=30, Completed, Sponsor: University of Alabama at Birmingham
N=3180 --> 872 Active, not recruiting --> Completed
- ||| anastrozole / Generic mfg.
Trial completion, Compliance, Adherence: ARTEMIS: Arimidex Therapy Compliance Electronic Monitoring System (clinicaltrials.gov) - Aug 31, 2011
P=N/A, N=104, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || anastrozole / Generic mfg., fulvestrant / Generic mfg., exemestane / Generic mfg.
Trial completion, Metastases: Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) (clinicaltrials.gov) - Aug 25, 2011
P3, N=25, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | anastrozole / Generic mfg.
New P2 trial: PARAGON - Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms (EUDRACT) - Aug 22, 2011
P2, N=150, Ongoing, Sponsor: Greater Glasgow and Clyde`University of Glasgow